IOLCP
1 call
Concalls & earnings callsIOL Chemicals & Pharmaceuticals Ltd
Every summarised call, newest first. Latest is Q1 FY27, held 13 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →Strong Q1 growth driven by successful diversification beyond ibuprofen, with non-ibu APIs contributing 43% of pharma revenue and a 60.7% EBITDA increase.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | ₹756 Cr | 37% | |
| EBITDA | ₹111 Cr | 60.7% | |
| PAT | ₹64.5 Cr | 89.9% | |
| EBITDA Margin | 14.6% | — |
Latest guidance
- FY27 revenue growth of 15% to 20%.
- FY27 EBITDA margin in the range of 14% to 15%.
- Export contribution of approximately 25% to 30% of revenue for FY27.
- Current plan for FY28 is ~15-20% top line growth and EBITDA margin of 15-17%, subject to scenario.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹523.30 Cr+0.6% YoY-0.5% QoQ | ₹20.53 Cr-11% YoY+7.2% QoQ | ₹3.50-10.9% YoY+7.4% QoQ |
| Q2 FY25 | ₹525.75 Cr-3.6% YoY+4.7% QoQ | ₹19.15 Cr-49.4% YoY-36.1% QoQ | ₹3.26-49.5% YoY-36.2% QoQ |
| Q1 FY25 | ₹502.38 Cr-10.8% YoY-0.3% QoQ | ₹29.97 Cr-34.6% YoY+8.5% QoQ | ₹5.11-34.6% YoY+8.5% QoQ |
| Q4 FY24 | ₹503.92 Cr-14.2% YoY-3.2% QoQ | ₹27.62 Cr-57.4% YoY+19.7% QoQ | ₹4.71-57.3% YoY+19.8% QoQ |
| Q3 FY24 | ₹520.39 Cr-0.6% YoY-4.6% QoQ | ₹23.08 Cr-3% YoY-39.1% QoQ | ₹3.93-3% YoY-39.1% QoQ |
Call history
- Q1 FY27Positive tone
Strong Q1 growth driven by successful diversification beyond ibuprofen, with non-ibu APIs contributing 43% of pharma revenue and a 60.7% EBITDA increase.
- Revenue
- ₹756 Cr37%
- EBITDA
- ₹111 Cr60.7%